MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma

Summary

This is a Phase 2a, open-label, parallel group, partly randomized dose escalation trial to assess the safety and efficacy of a low dose, an intermediate dose, and high dose MSB0010445 given by intravenous infusion to subjects with advanced (unresectable or metastatic) melanoma in combination with stereotactic body radiation therapy (SBRT).

Timeline

Start

2014-01

Primary completion

2015-04

Completion

2015-06

Outcome

Outcome not reported

Stopped: “The study is terminated prematurely as the sponsor decided to discontinue program of NHS-IL2 \[MSB0010445\]”

Drugs

Indications